Definium Therapeutics, Inc. DFTX

Investing.com -- Jefferies identified three biotechnology stocks that appear undervalued with strong commercial prospects despite a challenging macro environment. The firm noted that rising interest rates are pressuring small and mid-cap biotech companies, potentially shifting investor focus toward late-stage and commercial-stage names. All three of the highlighted stocks are positioned to launch products with significant peak sales potential.

NEW YORK, September 28, 2026--Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to fifteen newly hired non-executive employees consisting of options to purchase an aggregate of 334,810 common shares of the Company (the "Options") with effective grant dates of Septembe

Key Takeaways; Psychedelic Sector Optimi Health Plans to Initiate Phase 3 Clinical Trial Evaluating MDMA Therapy for Individuals with PTSD Eli Lilly Completed $2.8 Billion Acquisition of AtaiBeckley, Expanding its Mental Health Pipeline Definium’s Phase 3 Panorama Trial Delivered Positive Results for DT120 in Generalized Anxiety Disorder Psyence BioMed Established Texas Entity to Advance U.S. […]

Definium Therapeutics, Inc. (NASDAQ:DFTX) has now delivered a third consecutive positive Phase 3 readout for its LSD-based medication, the second in generalized anxiety disorder. The result puts the company on a viable route toward a potential FDA approval of an LSD-based treatment for generalized anxiety disorder, and considering how closely psychedelic stocks have historically traded on […]

Large-cap healthcare outperformed this week: XLV gained 1.4% through Tuesday, while XBI fell 1.4% and IBB declined 0.5%.

Definium Therapeutics has ridden a powerful three year run, and that surge now puts a spotlight on a simple question for investors who care about balance sheets. Is the current share price still grounded in what the business is worth on its books, or has sentiment pulled it away from its underlying equity value? Over the past three years, Definium Therapeutics has delivered a return of roughly 8.9x, which raises the stakes for whether the stock price still lines up with the value recorded on...

Definium Therapeutics plans to submit an NDA for DT120 in GAD In the first half of 2027.

Definium Therapeutics recently reported that its Phase 3 Panorama trial of DT120, an LSD-based orally disintegrating tablet, in adults with generalized anxiety disorder met the primary and all key secondary endpoints, with a single 100 µg dose delivering a statistically significant 5.1‑point placebo‑adjusted reduction in HAM‑A anxiety scores at Week 12. The data also showed early and durable symptom relief from just one treatment, with meaningful improvements as soon as Day 2 and no new...

Definium Therapeutics (DFTX) just reported that its second Phase 3 Panorama trial of DT120 ODT in generalized anxiety disorder met primary and key secondary endpoints, with clinically meaningful, placebo adjusted improvements in anxiety measures. Definium Therapeutics shares have rallied strongly, with a 90 day share price return of 66.6% and a year to date share price gain of 195.09%. The 1 year total shareholder return of 321.47% signals powerful momentum that the latest Phase 3 success...

Definium Therapeutics' LSD eased the symptoms of anxiety, the company said Monday as shares took off again.

Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.

Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares rose 20% after the company reported topline results from its Phase 3 Panorama study evaluating DT120 ODT in patients with generalized anxiety disorder.

NEW YORK, September 14, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet (ODT) in adults with generalized anxiety disorder (GAD). This is the Company’s thi